TOO GOURMET, INC. CHANGES NAME, TRADING SYMBOL, AND CUSIP
                           NUMBER

Irvine, California November 18, 2003:  Global Life Sciences,
Inc.,-OTC: GBLS (formerly known as Too Gourmet, Inc. (TGOU) today
announced that it has changed its name to "Global Life Sciences,
Inc." in connection with its acquisition of Internationale
Fachklinik, a German medical laboratory and service provider.
The name change is effective Tuesday, November 18, 2003.  In
addition, the company announced that, effective at the opening of
the markets on Wednesday, November 19, 2003, the company's new
trading symbol is "GBLS" and its new Cusip number is "379374 10 1."

About Global Life Sciences, Inc.:

Global Life Sciences, Inc. owns and operates a medical laboratory
specializing in the research, analysis, and in vitro diagnosis of
live biopsy tissue samples for allergic, immunological, and
environmentally related disorders. In order to improve the
quality of test results, Prof. Reimann, the company's Chairman,
Chief Executive Officer and President, developed and patented a
unique device known as a "Tabox", which enables the precise
analysis of the effects of allergens and toxins on the human body
in an in vitro environment.

Currently, the company operates a total of 28 inter-clinic Tabox
systems as proprietary devices, which are available to
practitioners, clinics and other medical customers on a fee-for-
service basis. The company anticipates the production and use of
up to 100 Tabox systems by its medical customers by the end of
the third quarter 2004. In addition, new labs, research
facilities and integrated out-patient clinics are currently
projected to be established in Zurich (Switzerland) and Berlin
(Germany) during 2004 and 2005.

The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements.  Certain
information included in this press release contains statements
that are forward-looking, such as statements related to the
future anticipated direction of the industry, plans for future
expansion, various business development activities, planned
capital expenditures, future funding sources, anticipated sales
growth, and potential contracts.  Such forward-looking
information involves important risks and uncertainties that could
significantly affect anticipated results in the future and,
accordingly, such results may differ from those expressed in any
forward-looking statements made by, or on behalf of Too Gourmet,
Inc.  These risks and uncertainties include, but are not limited
to, those relating to development and expansion activities,
dependence on existing management, financing activities, and
domestic and global economic conditions.


Investor Contact:
Global Life Sciences, Inc.
Attention:  c/o  R. Katz
Phone:  949-223-7103


Business Contact:
Global Life Sciences, Inc.
Attention:  Prof. Dr. Reimann
Fax:  +49-4503-707532